[Form 4] ANI Pharmaceuticals, Inc. Insider Trading Activity

Antonio R. Pera, a director of ANI Pharmaceuticals, Inc. (ANIP), reported a sale of 7,292 shares of the company on 09/03/2025 at a price of $94.94 per share.

Rhea-AI Filing Summary

Antonio R. Pera, a director of ANI Pharmaceuticals, Inc. (ANIP), reported a sale of 7,292 shares of the company on 09/03/2025 at a price of $94.94 per share. After the transaction, Mr. Pera beneficially owned 22,660 shares. The Form 4 was signed by an attorney-in-fact and filed following the transaction.

Insights

Financial Analyst

TL;DR: Insider sale of 7,292 shares reduces holdings to 22,660; transaction appears routine with no additional context provided.

The filing discloses a straightforward open-market disposition by a company director at $94.94 per share. Without timing context around other insider activity, earnings, or material corporate events in this filing, the transaction alone provides limited insight into company fundamentals. Size of sale relative to total holdings is disclosed, allowing investors to quantify the change in direct ownership.

Corporate Governance Expert

TL;DR: Director reported a standard Form 4 sale; documentation and signature by attorney-in-fact meet procedural requirements.

The Form 4 correctly reports the director relationship, transaction date, number of shares sold, sale price, and resulting beneficial ownership. The signature by attorney-in-fact is noted and dated. The filing does not indicate use of a Rule 10b5-1 plan or any derivative transactions. From a governance perspective, the disclosure is compliant but offers no further governance signals.

Insider Trade Summary

Net Seller: 7,292 shares

Net Sell 1 txn

Insider Pera Antonio R

Role Director

Sold 7,292 shs ($692K)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,292	$94.94	$692K

Holdings After Transaction: Common Stock — 22,660 shares (Direct)

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/04/2025 - 04:44 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pera Antonio R

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2025		S		7,292	D	$94.94	22,660	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Antonio R. Pera, by attorney-in-fact Meredith W. Cook	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.